Precision Medicine in Cancer

Precision cancer medicine is an approach that tailors treatment to the unique genetic, molecular, and clinical features of each patient and their disease, enabling more targeted and personalized therapeutic strategies aimed at maximizing efficacy and minimizing toxicity.

Cancer is highly heterogeneous, or diverse; one-size-fits-all treatments are insufficient.

• Advances in genomics, biomarkers, AI, and data analytics enable personalized therapies.
• Improves patient outcomes: more effective, fewer side effects.

Vision

To lead globally as an academic health system advancing precision medicine in cancer care, continuously evolving through integration of science, technology, and clinical trials; promoting collaboration, differences in populations and ethical data stewardship; delivering real-world clinical impact; and shaping a lasting impact through education.

The PMTB is grounded in several core aims: to increase active participation across specialties; to expand educational opportunities for trainees at all levels; and to promote appropriate referral of patients to clinical trials, particularly Phase I studies. The tumor board also strives to generate scholarly output, such as case-based publications or analyses arising from recurring molecular or diagnostic themes, and to continue strengthening multidisciplinary collaboration among hematology/oncology, molecular genetics, pathology, bioinformatics, biostatistics, molecular genetics, pathology, bioinformatics, biostatistics, clinical trials teams, and IT/EHR partners. Through these efforts, the PMTB advances Yale Cancer Center’s mission of embedding precision medicine into routine clinical practice.

In general, the PMTB is organized into two complementary formats: PMTB-A, focused on general clinical case discussions, and PMTB-B, designed for in-depth, didactic case analysis. Each format serves distinct educational and clinical objectives while promoting cross-specialty engagement.

At the same time, the PMTB structure remains intentionally flexible, allowing adaptation to evolving clinical needs, unusual diagnostic challenges, or novel molecular findings. This flexibility ensures that the tumor board functions not only as a clinical decision-support platform but also as a dynamic learning environment and a catalyst for innovation, fostering a collaborative culture across the cancer center.